Celecoxib augmentation of continuously Ill patients with schizophrenia
Celecoxib augmentation of continuously Ill patients with schizophrenia
复制标题
DOI：
10.1016/j.biopsych.2005.02.024
复制
发表时间：
2005-06-15
影响因子：
10.6
通讯作者：
Dolnak, D
中科院分区：
文献类型：
--
作者：
Rapaport, MH;Delrahim, KK;Dolnak, D
背景资料：先前的报告已经证明塞来昔布治疗精神分裂症急性加重患者的有益效果。我们研究了塞来昔布加强非典型抗精神病药物治疗持续症状的精神分裂症门诊患者的效果，以进一步扩展这些发现。我们假设，塞来昔布增强治疗，将改善精神病理学评级相比，安慰剂。方法：38个有症状的门诊受试者符合DSM-IV标准的精神分裂症和稳定关闭的非典型抗精神病药物治疗至少三个月，随机接受8周的双盲安慰剂或塞来昔布（400毫克/天）增强。精神病理学，功能障碍，锥体外系副作用的措施进行了整个study.Results：治疗队列没有任何不同的临床结果的措施，结论：塞洛昔布增强连续患病门诊精神分裂症患者没有改善临床症状或残疾的措施。
Background: Previous reports have demonstrated a beneficial effect of celecoxib adjunctive therapy for patients with an acute exacerbation of schizophrenia. We investigated the effects of celecoxib augmentation of atypical antipsychotic medications for continuously symptomatic outpatient subjects with schizophrenia to further extend these findings. We hypothesized that celecoxib augmentation therapy, would improve psychopathology ratings compared with placebo.Methods: Thirty-eight symptomatic outpatient subjects meeting DSM-IV criteria for schizophrenia and on a stable close of an atypical antipsychotic medication for at least three months were randomized to receive 8 weeks of double blind placebo or celecoxib (400 mg/day) augmentation. Measures of psychopathology, functional disability, and extrapyramidal side effects were performed throughout the study.Results: The treatment cohorts did not differ on any of the clinical outcome measures,Conclusions: Celocoxib augmentation of continuously ill outpatient subjects with schizophrenia did not improve clinical symptoms or measures of disability.